A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.
Clinical Trial Grant
Awarded By
Dana-Farber Cancer Institute
Start Date
October 1, 2015
End Date
May 10, 2024
Awarded By
Dana-Farber Cancer Institute
Start Date
October 1, 2015
End Date
May 10, 2024